Volume 19 Issue 2
Feb.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(2): 290-292,297
CHEN Lu-xin, GU Dong-mei, LUO Wei. Advances in the research of thrombopoietin[J]. Chinese Journal of General Practice, 2021, 19(2): 290-292,297. doi: 10.16766/j.cnki.issn.1674-4152.001791
Citation: CHEN Lu-xin, GU Dong-mei, LUO Wei. Advances in the research of thrombopoietin[J]. Chinese Journal of General Practice, 2021, 19(2): 290-292,297. doi: 10.16766/j.cnki.issn.1674-4152.001791
shu

Advances in the research of thrombopoietin

doi: 10.16766/j.cnki.issn.1674-4152.001791

  • Department of Clinical Laboratory, General Hospital of Tianjin Medical University, Tianjin 300052, China

Funds:

 81701968

 2018KJ059

 ZYYFY2016024

  • Received Date: 2020-05-06
    Available Online: 2022-02-19
    Abstract
  • Thrombopoietin (TPO) is a key regulator in platelet production, and also known as a megakaryocyte growth-derived factor. TPO can bind to c-Mpl, a surface receptor on megakaryocytes, activate megakaryocytes through a variety of signaling pathways to promote the proliferation and differentiation of megakaryocytes to produce platelets, and then achieve the purpose of increasing platelet levels in circulation. Now, TPO has been isolated and cloned at home and abroad, a lot of research has been done on its protein structure, expression regulation, biological activity and its therapeutic effect in clinical diseases. These studies revealed new sources of TPO and their similarities and differences with erythropoietin (EPO) structure, the maintenance mechanism of TPO concentration in vivo, and the advantages and disadvantages of TPO drugs of different generations. At the same time, TPO was reported not only in common platelets reducing diseases have a good therapeutic effect, and also have positive protective effects on the other organs or cells except the blood system, such as aplastic anemia, myelodysplastic syndrome, liver cirrhosis and so on. This series of research developments has an important guiding significance for the clinical application of TPO. This article reviews the latest developments mentioned above.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    GEDDIS A E, LINDEN H M, KAUSHANSKY K. Thrombopoietin: a pan-hematopoietic cytokine[J]. Cytokine Growth Factor Rev, 2002, 13(1): 61-73. doi: 10.1016/S1359-6101(01)00030-2
    [2]
    GROZOVSKY R, GIANNINI S, FALET H, et al. Novel mechanisms of platelet clearance and thrombopoietin regulation[J]. Curr Opin Hematol, 2015, 22(5): 445-451. doi: 10.1097/MOH.0000000000000170
    [3]
    CHO J, KIM H, SONG J, et al. Platelet storage induces accelerated desialylation of platelets and increases hepatic thrombopoietin production[J]. J Transl Med, 2018, 16(1): 199. doi: 10.1186/s12967-018-1576-6
    [4]
    KATO T, MATSUMOTO A, OGAMI K, et al. Native thrombopoietin: structure and function[J]. Stem Cells, 1998, 16(5): 322-328. doi: 10.1002/stem.160322
    [5]
    MUTO T, FEESE M D, SHIMADA Y, et al. Functional analysis of the C-terminal region of recombinant human thrombopoietin. C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion[J]. J Biol Chem, 2000, 275(16): 12090-12094. doi: 10.1074/jbc.275.16.12090
    [6]
    HITCHCOCK I S, KAUSHANSKY K. Thrombopoietin from beginning to end[J]. Br J Haematol, 2014, 165(2): 259-268. doi: 10.1111/bjh.12772
    [7]
    KUTER D J. Milestones in understanding platelet production: a historical overview[J]. Br J Haematol, 2014, 165(2): 248-258. doi: 10.1111/bjh.12781
    [8]
    KAUSHANSKY K. Thrombopoiesis[J]. Semin Hematol, 2015, 52(1): 4-11. doi: 10.1053/j.seminhematol.2014.10.003
    [9]
    GHILARDI N, WIESTNER A, SKODA R C. Thrombopoietin production is inhibited by a translational mechanism[J]. Blood, 1998, 92(11): 4023-4030. doi: 10.1182/blood.V92.11.4023
    [10]
    KATO T, ODA A, INAGAKI Y, et al. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin[J]. Proc Natl Acad Sci U S A, 1997, 94(9): 4669-4674. doi: 10.1073/pnas.94.9.4669
    [11]
    GROZOVSKY R, BEGONJA A J, LIU K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling[J]. Nat Med, 2015, 21(1): 47-54. doi: 10.1038/nm.3770
    [12]
    PECCI A, RAGAB I, BOZZI V, et al. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim[J]. EMBO Mol Med, 2018, 10(1): 63-75. doi: 10.15252/emmm.201708168
    [13]
    LEBOIS M, DOWLING M R, GANGATIRKAR P, et al. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling[J]. J Thromb Haemost, 2016, 14(9): 1882-1887. doi: 10.1111/jth.13397
    [14]
    ZHANG J, LIANG Y, AI Y, et al. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review[J]. Expert Opin Pharmacother, 2017, 18(15): 1543-1551. doi: 10.1080/14656566.2017.1373091
    [15]
    MAKAR R S, ZHUKOV O S, SAHUD M A, et al. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists[J]. Am J Hematol, 2013, 88(12): 1041-1044. doi: 10.1002/ajh.23562
    [16]
    AI-SAMKARI H, MARSHALL A L, GOODARZI K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors[J]. Haematologica, 2018, 103(4): 169-172. doi: 10.3324/haematol.2017.180166
    [17]
    CANTONI S, CARPENEDO M, MAZZUCCONI M G, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers[J]. Am J Hematol, 2018, 93(1): 58-64. doi: 10.1002/ajh.24935
    [18]
    THACHIL J, BAGOT C, BRADBURY C, et al. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists[J]. Br J Haematol, 2018, 180(4): 591-594. doi: 10.1111/bjh.14395
    [19]
    NEUNERT C, DESPOTOVIC J, HALEY K, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of north America ICON2 study[J]. Pediatr Blood Cancer, 2016, 63(8): 1407-1413. doi: 10.1002/pbc.26003
    [20]
    BUSSEL J B, LAKKARAJA M. Thrombopoietic agents: there is still much to learn[J]. Presse Med, 2014, 43(4Pt2): e69-78. http://www.em-consulte.com/showarticlefile/883935/main.pdf
    [21]
    OLNES M J, SCHEINBERG P, CALVO K R, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia[J]. N Engl J Med, 2012, 367(1): 11-19. doi: 10.1056/NEJMoa1200931
    [22]
    DESMOND R, TOWNSLEY D M, DUMITRIU B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug[J]. Blood, 2014, 123(12): 1818-1825. doi: 10.1182/blood-2013-10-534743
    [23]
    GILL H, LEUNG G M, LOPES D, et al. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia[J]. Br J Haematol, 2017, 176(6): 991-994. doi: 10.1111/bjh.14024
    [24]
    WANG H, DONG Q, FU R, et al. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy[J]. Biomed Res Int, 2015, 2015: 597293. doi: 10.1007/s40265-015-0363-4
    [25]
    BART-SMITH E E, KORDASTI S, KULASEKARARAJ A G, et al. Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role[J]. AIDS, 2014, 28(18): 2786-2788. doi: 10.1097/QAD.0000000000000504
    [26]
    TOWNSLEY D M, DESMOND R, DUNBAR C E, et al. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes[J]. Int J Hematol, 2013, 98(1): 48-55. doi: 10.1007/s12185-013-1352-6
    [27]
    张凤奎, 杜俊. 血小板生成素受体激动剂改善重型再生障碍性贫血疗效的研究进展[J]. 中华血液学杂志, 2017, 38(9): 813-816.
    [28]
    KANTARJIAN H, FENAUX P, SEKERES M A, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia[J]. J Clin Oncol, 2010, 28(3): 437-444. doi: 10.1200/JCO.2009.24.7999
    [29]
    SVENSSON T, CHOWDHURY O, GARELIUS H, et al. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine[J]. Eur J Haematol, 2014, 93(5): 439-445. doi: 10.1111/ejh.12383
    [30]
    MERLI P, STROCCHIO L, VINTI L, et al. Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother[J], 2015, 16(14): 2243-2256. doi: 10.1517/14656566.2015.1085512
    [31]
    AFDHAL N H, GIANNINI E G, TAYYAB G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia[J]. N Engl J Med, 2012, 367(8): 716-724. doi: 10.1056/NEJMoa1110709
    [32]
    CHAN S, CHAN G C, YE J, et al. Thrombopoietin protects cardiomyocytes from iron-overload induced oxidative stress and mitochondrial injury[J]. Cell Physiol Biochem, 2015, 36(5): 2063-2071. doi: 10.1159/000430173
    [33]
    WU W, ZHONG W, LANG B, et al. Thrombopoietin could protect cerebral tissue against ischemia-reperfusion injury by suppressing NF-kappaB and MMP-9 expression in rats[J]. Int J Med Sci, 2018, 15(12): 1341-1348. doi: 10.7150/ijms.27543
    [34]
    LUM S H, GRAINGER J D. Eltrombopag for the treatment of aplastic anemia: current perspectives[J]. Drug Des Devel Ther, 2016, 10: 2833-2843. doi: 10.2147/DDDT.S95715
    [35]
    徐倩, 周敏. 血小板生成素受体激动剂儿童用药的研究进展[J]. 中国小儿血液与肿瘤杂志, 2018, 23(5): 229-231. doi: 10.3969/j.issn.1673-5323.2018.05.002
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (885) PDF downloads(24) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return